神经退化性疾病市场规模、份额、成长分析（按药物类别、适应症、给药途径、最终用户和地区）- 产业预测，2025 年至 2032 年

2023 年全球神经退化性疾病市场规模价值 526 亿美元，预计将从 2024 年的 563.9 亿美元增长到 2032 年的 983.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.2%。

在诊断和治疗技术的进步、政府资金的增加以及患者人口结构变化的推动下，全球神经退化性疾病市场正在经历显着增长。创新的医疗基础设施和有针对性的研究计划正受到关注，特别是针对老年痴呆症、帕金森氏症和肌萎缩侧索硬化症等疾病。透过整合人工智慧和机器学习技术来分析脑部扫描、识别病情进展和定製药物反应，提高治疗效果和诊断准确性正在重塑产业。先进医疗平台的出现支援即时远端监控和患者与神经科之间的无缝资料交换，从而促进及时干预。此外，对永续性和成本效益的关注正在推动可携式节能诊断工具的设计。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

神经退化性疾病市场规模（依药物类别和复合年增长率） (2025-2032)

• 市场概览
• 免疫调节剂
• 干扰素
• 脱羧酶抑制剂
• 促效剂
• 其他的

神经退化性疾病市场规模（按适应症和复合年增长率）（2025-2032）

• 市场概览
• 多发性硬化症
• 帕金森氏症
• 阿兹海默症
• 脊髓性肌肉萎缩症（SMA）
• 其他的

神经退化性疾病市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 口服
• 注射
• 经皮

神经退化性疾病市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院药房
• 零售药局
• 网路药局

神经退化性疾病市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Orion Pharma
• UCB SA
• ACADIA Pharmaceuticals Inc.
• Lundbeck A/S

结论和建议

Global Neurodegenerative Disease Market size was valued at USD 52.6 billion in 2023 and is poised to grow from USD 56.39 billion in 2024 to USD 98.34 billion by 2032, growing at a CAGR of 7.2% during the forecast period (2025-2032).

The global neurodegenerative disease market is experiencing significant growth, propelled by advancements in diagnostic and treatment technologies, increased government funding, and evolving patient demographics. Innovative healthcare infrastructures and targeted research initiatives are gaining prominence, particularly for conditions such as Alzheimer's, Parkinson's, and ALS. Enhancements in treatment efficacy and diagnostic accuracy are reshaping the industry, with the integration of AI and machine learning techniques to analyze brain scans, identify disease progression, and tailor medication responses. The emergence of advanced medical platforms supports real-time remote monitoring and seamless data exchange between patients and neurologists, facilitating timely interventions. Furthermore, a focus on sustainability and cost-efficiency is driving the design of portable, energy-efficient diagnostic tools, ensuring greater accessibility in underserved areas while enabling continuous patient evaluation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurodegenerative Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neurodegenerative Disease Market Segments Analysis

Global Neurodegenerative Disease Market is segmented by Drug Class, Disease Indication, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists and Others. Based on Disease Indication, the market is segmented into Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA) and Others. Based on Route of Administration, the market is segmented into Oral, Injection and Transdermal. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neurodegenerative Disease Market

Advancements in diagnostic technologies such as PET scans, biomarker-focused blood tests, and AI-driven neuroimaging have significantly improved the early and accurate identification of neurodegenerative diseases. These innovations enhance patient management and treatment outcomes through timely detection. Consequently, the global market is experiencing growth across diagnostic, therapeutic, and monitoring sectors, driven by these developments. This surge is further fostering an increase in clinical trials and research investments, as the focus on effective solutions for neurodegenerative conditions intensifies. As a result, the landscape of the neurodegenerative disease market is evolving, reflecting the urgent need for improved therapies and diagnostics.

Restraints in the Global Neurodegenerative Disease Market

The Global Neurodegenerative Disease market faces significant challenges due to the high costs associated with advanced therapies, which often include expensive medications, continuous care, and specialized diagnostic tools. These financial barriers particularly affect patients in low- and middle-income countries, limiting their access to innovative treatments such as gene therapy and monoclonal antibodies. The burden of substantial out-of-pocket expenses hampers the adoption of these therapies, leading to delays in early intervention. Consequently, this situation adversely affects the long-term health outcomes for patients across various regions, exacerbating the existing disparities in healthcare accessibility and treatment effectiveness.

Market Trends of the Global Neurodegenerative Disease Market

The global neurodegenerative disease market is witnessing a significant trend driven by the integration of artificial intelligence (AI) in diagnostics. This technological advancement enables early detection of conditions like Alzheimer's by analyzing patient histories, blood biomarkers, and brain scans with remarkable precision. As AI algorithms enhance diagnosis speed and clinical accuracy, healthcare providers are increasingly adopting these tools, resulting in a more proactive approach to neurodegenerative disease management. This shift not only facilitates timely interventions but also fosters improved patient outcomes, thereby solidifying AI's role as a pivotal catalyst for growth in the neurodegenerative diseases market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Neurodegenerative Disease Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Immunomodulator
• Interferons
• Decarboxylase Inhibitors
• Dopamine Agonists
• Others

Global Neurodegenerative Disease Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Multiple Sclerosis
• Parkinson's Disease
• Alzheimer's Disease
• Spinal Muscular Atrophy (SMA)
• Others

Global Neurodegenerative Disease Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection
• Transdermal

Global Neurodegenerative Disease Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Neurodegenerative Disease Market Size & CAGR (2025-2032)

• North America (Drug Class, Disease Indication, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Class, Disease Indication, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Indication, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Indication, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Indication, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACADIA Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations